AventaMed’s co-founders are Olive O’Driscoll, CEO and John Vaughan, CTO. They invented the Solo TTD and incorporated the company in 2013. Together with their team, Board and Clinical Advisors they are wholly dedicated to the commercial success of the product and improving pediatric quality of care. AventaMed was crowned Seedcorn’s Overall Winner for the Best Early Stage Company in 2014 and Emerging Medtech Company of the Year, Irish Medical Device Association (IMDA) in 2015. Since then, AventaMed has raised two investment rounds, securing more than €3m in funding. The AventaMed team have successfully completed clinical studies, achieved CE Mark regulatory approval of the Solo TTD device in Europe. They are now focused on European commercialization and gaining FDA clearance for Solo TTD.
BOARD OF DIRECTORS
Jack Cashman Board Chairman and Bernard Lim, Non-Executive Director bring over 50 years of medical device commercialization experience to the AventaMed team. Both have built companies from grass roots through to revenue and successful exits.
Olive O’Driscoll, CEO and co-founder
Olive is a biomedical engineer with 18 years’ experience in the medical device and pharmaceutical industry. She has worked in multi-national and start-up companies in business, clinical and regulatory roles in the areas of oncology, cardiovascular and orthopedics. Olive has led international clinical trials with more than 15,000 patients in 200 countries, with subsequent EU and USA clearances. Having invented and developed the Solo TTD, Olive set up AventaMed with co-founder John Vaughan in 2013.
John Vaughan, CTO and co-founder
John has over 15 years of experience in the medical device industry and has worked for numerous large medical device companies such as Stryker and Guidant. He is most experienced in medical device product development, strategic regulatory planning, regulatory approval, IP development and product realization. He has invented, designed and commercially launched numerous products worldwide. He is also an inventor on over 50 patents.
Jack Cashman, Chairman and Non-Executive Director
Jack Cashman has held senior positions in International business and been a Board member for several companies in North America and Europe. He is now a Director of Telesat Holdings Inc. (Canada) and Mettrum Health Corp. (Canada). He was Chairman of Vectura Plc taking it public on the London Stock Exchange and Chairman and joint-CEO of RP Scherer, taking it public on The New York Stock Exchange.
Bernard Lim, Non-Executive Director
Bernard Lim founded a medical devices company and led its growth and sale to a global pharmaceutical. In addition, he has led and grown companies spanning biotechnology, diagnostics, medtech, electronics and high technology across US, Canada and Europe in leadership roles as Chair, CEO and SVP. In addition to AventaMed, Bernard is Chair and CEO of Andersdx (UK), Chair of Altus Assessments (Canada) and Executive-in-Residence, Ontario Regional Innovation Centre (Canada).
Bruce Clibborn, Board member
Bruce is a lead investor with Boole, Ireland’s most active angel investment syndicate where he has evaluated and led investments in medical devices and software companies since 2011. He began his career as an engineer designing HIPAA-compliant electronic data storage solutions for the US healthcare industry with pioneering cloud storage hardware manufacturer Raidtec.
Bruce graduated with a BA in Electronic and Microelectronic Engineering from Trinity College Dublin and has an MBA in Finance from London Business School.